Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - capsule - each capsule contains cefalexin monohydrate equiv. to cefalexin 250,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - capsule - each capsule contains cefalexin monohydrate equiv. to cefalexin 500,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 250,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 500,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 1000,0 mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela sa-nv - cefalexin monohydrate 263 mg - eq. cefalexin 250 mg - tablet - 250 mg - cefalexin monohydrate 263 mg - cefalexin - dog

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela sa-nv - cefalexin monohydrate 52,6 mg - eq. cefalexin 50 mg - tablet - 50 mg - cefalexin monohydrate 52.6 mg - cefalexin - dog

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg;   - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml;   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.